Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Discovery of BAY-985, a highly selective TBK1/IKK epsilon inhibitor.


Rengachari,  S.
Department of Molecular Biology, MPI for Biophysical Chemistry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)

(Supplementary material), 7KB

(Supplementary material), 711KB


Lefranc, J., Schulze, V. K., Hillig, R. C., Briem, H., Prinz, F., Mengel, A., et al. (2020). Discovery of BAY-985, a highly selective TBK1/IKK epsilon inhibitor. Journal of Medicinal Chemistry, 63(2), 601-612. doi:10.1021/acs.jmedchem.9b01460.

Cite as: https://hdl.handle.net/21.11116/0000-0005-9B80-B
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKK epsilon are noncanonical members of the inhibitor of the nuclear factor kappa B (I kappa B) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKK epsilon inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.